Side effects of the Immunte checkpoint inhibitors
Posted: Tue Feb 16, 2016 9:15 am
Managing the Side Effects of Novel Cancer Immunotherapeutics
Recognising and controlling the adverse effects of CTLA-4 and PD-1 blocking agents
Date: 17 Mar 2014
Topic: Immuno-oncology
In a review article published in the February 2014 issue of Nature Reviews Clinical Oncology, Drs Tara Gangadhar and Robert Vonderheide of the Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, describe the adverse-event profiles for several novel immune therapy approaches for cancer, and discuss the appropriate management of patients receiving these therapies.
The development of effective immune-based therapy in oncology presents challenges in recognising and managing treatment-related toxic effects. Immune therapies are associated with a variable and unique spectrum of toxic effects, as exemplified by treatment with IL-2 and high-dose interferon. Although most medical oncologists are familiar with their adverse-effect profile, the administration remains limited to specialised centres with experienced and highly-skilled clinical care teams, capable of providing the supportive care required for patients undergoing such therapy, owing to the risk of severe hypotension and organ failure during treatment.
Similarly, several novel immune therapy approaches are currently limited to a few clinical research centres. Therefore, the authors recognise the educational needs and describe in their article the toxicity profiles of agents that block immune checkpoints, immunostimulatory agents, and adoptive T-cell therapy.
http://www.esmo.org/Oncology-News/Manag ... erapeutics
Recognising and controlling the adverse effects of CTLA-4 and PD-1 blocking agents
Date: 17 Mar 2014
Topic: Immuno-oncology
In a review article published in the February 2014 issue of Nature Reviews Clinical Oncology, Drs Tara Gangadhar and Robert Vonderheide of the Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, describe the adverse-event profiles for several novel immune therapy approaches for cancer, and discuss the appropriate management of patients receiving these therapies.
The development of effective immune-based therapy in oncology presents challenges in recognising and managing treatment-related toxic effects. Immune therapies are associated with a variable and unique spectrum of toxic effects, as exemplified by treatment with IL-2 and high-dose interferon. Although most medical oncologists are familiar with their adverse-effect profile, the administration remains limited to specialised centres with experienced and highly-skilled clinical care teams, capable of providing the supportive care required for patients undergoing such therapy, owing to the risk of severe hypotension and organ failure during treatment.
Similarly, several novel immune therapy approaches are currently limited to a few clinical research centres. Therefore, the authors recognise the educational needs and describe in their article the toxicity profiles of agents that block immune checkpoints, immunostimulatory agents, and adoptive T-cell therapy.
http://www.esmo.org/Oncology-News/Manag ... erapeutics